PATIENT ENROLLMENT FORM
Use the TROGARZO® Enrollment Form to enroll your patients into the THERA patient support® Program.
DownloadMake undetectable possible1
For HTE patients with HIV whose current ARV regimen is failing and who need additional support to achieve long‑term suppression.1
For you and your patients.
Use the TROGARZO® Enrollment Form to enroll your patients into the THERA patient support® Program.
DownloadThe Billing & Coding Guide for TROGARZO® outlines the information needed to file a health insurance claim.
DownloadThe TROGARZO® THERA patient support® Program HCP leave behind explains the THERA patient support® Program benefits and services to you and your patients.
DownloadThe TROGARZO® THERA patient support® Patient Leave Behind explains the THERA patient support® Program and the benefits to your patients.
DownloadAccess the full Prescribing Information for TROGARZO® for complete product information.
DownloadThe Dosing & Administration Guide for TROGARZO® provides an overview of the dosing and administration process for TROGARZO®.
DownloadThe ACTHIV OPERA Data poster describes the virologic effectiveness of ibalizumab clinical trial experience compared to real‑world clinical care without ibalizumab in the OPERA® Cohort.
DownloadThe TROGARZO® HCP leave behind describes the key data, dosing and administration, and benefits of TROGARZO® for you and your patients.
DownloadThe TROGARZO® Patient Information Brochure provides all pertinent information about TROGARZO® to your patients.
DownloadTalk to your Theratechnologies Representative
Call the THERA patient support® Program at 1‑833‑238-4372
TROGARZO® (ibalizumab‑uiyk), in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection in heavily treatment‑experienced adults with multidrug resistant HIV‑1 infection failing their current antiretroviral regimen.
TROGARZO® is contraindicated in patients with a prior hypersensitivity reaction to TROGARZO® or any components of the product.
To report suspected adverse reactions, contact THERA patient support® at 1‑833‑23THERA (1‑833‑238-4372) or FDA at 1‑800‑FDA-1088 or www.fda.gov/medwatch.